Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:19332096rdf:typepubmed:Citationlld:pubmed
pubmed-article:19332096lifeskim:mentionsumls-concept:C0086418lld:lifeskim
pubmed-article:19332096lifeskim:mentionsumls-concept:C0021760lld:lifeskim
pubmed-article:19332096lifeskim:mentionsumls-concept:C2350570lld:lifeskim
pubmed-article:19332096lifeskim:mentionsumls-concept:C0078058lld:lifeskim
pubmed-article:19332096lifeskim:mentionsumls-concept:C0004114lld:lifeskim
pubmed-article:19332096lifeskim:mentionsumls-concept:C0021764lld:lifeskim
pubmed-article:19332096lifeskim:mentionsumls-concept:C0387583lld:lifeskim
pubmed-article:19332096lifeskim:mentionsumls-concept:C0200760lld:lifeskim
pubmed-article:19332096lifeskim:mentionsumls-concept:C0017262lld:lifeskim
pubmed-article:19332096lifeskim:mentionsumls-concept:C1171892lld:lifeskim
pubmed-article:19332096lifeskim:mentionsumls-concept:C0004083lld:lifeskim
pubmed-article:19332096lifeskim:mentionsumls-concept:C0936012lld:lifeskim
pubmed-article:19332096lifeskim:mentionsumls-concept:C2911684lld:lifeskim
pubmed-article:19332096lifeskim:mentionsumls-concept:C0185117lld:lifeskim
pubmed-article:19332096pubmed:issue6lld:pubmed
pubmed-article:19332096pubmed:dateCreated2009-6-1lld:pubmed
pubmed-article:19332096pubmed:abstractTextMalignant astrocytomas are highly vascular neoplasms with potent angiogenic activity. The present study aimed to investigate peripheral and local expression of interleukin (IL)-8 in astrocytomas with possible associations to IL-6, cyclooxygenase-2 (COX-2), vascular endothelial growth factor (VEGF) expression, and microvessel morphometry. IL-6- and IL-8-secreting peripheral blood monocytes (PBMCs) were evaluated in 17 glioblastoma (WHO grade IV), 5 anaplastic astrocytoma (WHO grade III), and 6 diffuse astrocytoma patients (WHO grade II), in parallel with 23 healthy controls using enzyme-linked immunosorbent spot (ELISPOT) assay. The IL-8 expression was assessed immunohistochemically in patients' tumor tissue sections and correlated with the expression of COX-2, VEGF, IL-6, and microvessel morphometry (assessed using CD34 antibody). Eighteen cases were also stained for CD31 and used as an additional vessel marker to validate our results regarding microvessel morphometry. IL-6 and IL-8 were highly secreted in the PBMCs of glioma patients compared with controls (p = 0.0001, p < 0.0001, respectively), with a positive correlation between IL-8 expression and secretion levels (p = 0.001). IL-8 immunoreactivity was detected in malignant cells or macrophages in perivascular areas and in pseudopalisading cells around necrosis and was positively correlated with histological grade (p = 0.0175) and tumor necrosis (p = 0.0793). IL-6 and IL-8 expression levels were positively correlated (p = 0.0036) and associated with COX-2 and VEGF expression (IL-6: p = 0.0133, p = 0.065; IL-8: p = 0.0139, p = 0.0101), but not with microvessel morphometry, by either CD31 or CD34. The coordinate expression and topographical relationship of IL-6, IL-8, COX-2, and VEGF in the same tumor areas (e.g., perinecrotic areas) attest to their intimate liaison in terms of cancer-induced angiogenesis, which is probably secondary to the induction of multiple interdependent molecular pathways. Moreover, our study seems to be the first attempt to link IL-8 expression by tumor cells with histological grade, implicating its potent role in gliomagenesis.lld:pubmed
pubmed-article:19332096pubmed:languageenglld:pubmed
pubmed-article:19332096pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19332096pubmed:citationSubsetIMlld:pubmed
pubmed-article:19332096pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19332096pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19332096pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19332096pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19332096pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19332096pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19332096pubmed:statusMEDLINElld:pubmed
pubmed-article:19332096pubmed:monthJunlld:pubmed
pubmed-article:19332096pubmed:issn1879-1166lld:pubmed
pubmed-article:19332096pubmed:authorpubmed-author:Korkolopoulou...lld:pubmed
pubmed-article:19332096pubmed:authorpubmed-author:PiperiChristi...lld:pubmed
pubmed-article:19332096pubmed:authorpubmed-author:KavantzasNiko...lld:pubmed
pubmed-article:19332096pubmed:authorpubmed-author:KalofoutisAna...lld:pubmed
pubmed-article:19332096pubmed:authorpubmed-author:BarbatisCalyp...lld:pubmed
pubmed-article:19332096pubmed:authorpubmed-author:LeaRobert WRWlld:pubmed
pubmed-article:19332096pubmed:authorpubmed-author:LevidouGeorgi...lld:pubmed
pubmed-article:19332096pubmed:authorpubmed-author:SamarasVassil...lld:pubmed
pubmed-article:19332096pubmed:authorpubmed-author:ZisakisAthana...lld:pubmed
pubmed-article:19332096pubmed:authorpubmed-author:Themistocleou...lld:pubmed
pubmed-article:19332096pubmed:authorpubmed-author:BoviatsisEfst...lld:pubmed
pubmed-article:19332096pubmed:issnTypeElectroniclld:pubmed
pubmed-article:19332096pubmed:volume70lld:pubmed
pubmed-article:19332096pubmed:ownerNLMlld:pubmed
pubmed-article:19332096pubmed:authorsCompleteYlld:pubmed
pubmed-article:19332096pubmed:pagination391-7lld:pubmed
pubmed-article:19332096pubmed:meshHeadingpubmed-meshheading:19332096...lld:pubmed
pubmed-article:19332096pubmed:meshHeadingpubmed-meshheading:19332096...lld:pubmed
pubmed-article:19332096pubmed:meshHeadingpubmed-meshheading:19332096...lld:pubmed
pubmed-article:19332096pubmed:meshHeadingpubmed-meshheading:19332096...lld:pubmed
pubmed-article:19332096pubmed:meshHeadingpubmed-meshheading:19332096...lld:pubmed
pubmed-article:19332096pubmed:meshHeadingpubmed-meshheading:19332096...lld:pubmed
pubmed-article:19332096pubmed:meshHeadingpubmed-meshheading:19332096...lld:pubmed
pubmed-article:19332096pubmed:meshHeadingpubmed-meshheading:19332096...lld:pubmed
pubmed-article:19332096pubmed:meshHeadingpubmed-meshheading:19332096...lld:pubmed
pubmed-article:19332096pubmed:meshHeadingpubmed-meshheading:19332096...lld:pubmed
pubmed-article:19332096pubmed:meshHeadingpubmed-meshheading:19332096...lld:pubmed
pubmed-article:19332096pubmed:meshHeadingpubmed-meshheading:19332096...lld:pubmed
pubmed-article:19332096pubmed:meshHeadingpubmed-meshheading:19332096...lld:pubmed
pubmed-article:19332096pubmed:meshHeadingpubmed-meshheading:19332096...lld:pubmed
pubmed-article:19332096pubmed:meshHeadingpubmed-meshheading:19332096...lld:pubmed
pubmed-article:19332096pubmed:meshHeadingpubmed-meshheading:19332096...lld:pubmed
pubmed-article:19332096pubmed:meshHeadingpubmed-meshheading:19332096...lld:pubmed
pubmed-article:19332096pubmed:year2009lld:pubmed
pubmed-article:19332096pubmed:articleTitleAnalysis of interleukin (IL)-8 expression in human astrocytomas: associations with IL-6, cyclooxygenase-2, vascular endothelial growth factor, and microvessel morphometry.lld:pubmed
pubmed-article:19332096pubmed:affiliationDepartment of Pathology, School of Medicine, National and Kapodistrian University of Athens, Laiko Hospital, Athens 11527, Greece.lld:pubmed
pubmed-article:19332096pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:19332096pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:19332096lld:pubmed